Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trialPaul M. Ridker, Hakan Kültürsay, Henry Krum et al.|The Lancet|2017Cited by 1.3k
Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trialPaul M. Ridker, Patrick Commerford, Jean MacFadyen et al.|The Lancet|2017Cited by 881
In-Hospital and 1-Year Mortality Associated with Diabetes in Patients with Acute Heart Failure: Results from the ESC-HFA Heart Failure Long-Term RegistryGiovanni Targher, Marco Dauriz, Cécile Laroche et al.|European Journal of Heart Failure|2016Cited by 171
Association Between Diabetes and 1-Year Adverse Clinical Outcomes in a Multinational Cohort of Ambulatory Patients With Chronic Heart Failure: Results From the ESC-HFA Heart Failure Long-Term RegistryMarco Dauriz, Giovanni Targher, Cécile Laroche et al.|Diabetes Care|2017Cited by 143